Dextromethorphan/quinidine - Avanir Pharmaceuticals
Alternative Names: AVP-923; Dextromethorphan HBr/quinidine sulfate; Dextromethorphan hydrobromide/quinidine sulfate; Neurodex; Nuedexta; Quinidine/dextromethorphan; ZenviaLatest Information Update: 05 Nov 2023
At a glance
- Originator Center for Neurologic Study
- Developer Avanir Pharmaceuticals
- Class Analgesics; Antimigraines; Antitussives; Behavioural disorder therapies; Cinchona alkaloids; Morphinans; Quinuclidines; Small molecules
- Mechanism of Action Cytochrome P-450 enzyme system inhibitors; NMDA receptor antagonists; Norepinephrine plasma membrane transport protein inhibitors; Serotonin plasma membrane transport protein inhibitors; Sigma-1 receptor agonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Emotional lability
- Discontinued Agitation; Diabetic neuropathies; Drug-induced dyskinesia; Migraine; Neuropathic pain
Most Recent Events
- 14 Feb 2019 Chemical structure information added
- 27 Nov 2018 No development reported - Phase-II for Agitation in USA (PO)
- 27 Nov 2018 No development reported - Phase-II for Migraine in USA (PO)